维普期刊资源整合服务平台（V6.5）

维普中文期刊产品整合服务

3篇 您的检索式：作者名="Xindi Zhou"

选中清除导出查看参考文献查看引证文献引用追踪共1页首页上一页第1页下一页末页 /1 跳转

		题名	作者	年代	出处	被引量
	1	Value of knee skin temperature measured by infrared thermography and soluble intercellular adhesion molecule-1 in the diagnosis of peri-prosthetic knee infection in Chinese individuals following total knee arthroplasty显示文摘	Mumingjiang Yishake Zhou Xindie He Rongxin	2014	Chinese Medical Journal2014，，17：	13
	2	Structure of the receptor-activated human TRPC6 and TRPC3 ion channels显示文摘TRPC6 和 TRPC3 是属于正规短暂受体潜力(TRPC ) 的家庭的激活受体的 nonselective 阳离子隧道隧道。他们被 diacylglycerol 激活,一个类脂化合物秒送信人。TRPC6 和 TRPC3 涉及许多生理的过程并且在人的基因疾病含有。这里我们在场在有最新识别的高亲密关系的禁止者 BTDM 的建筑群的人的 TRPC6 homotetramer 的结构由单个粒子的 cryo 电子显微镜学解决了到 3.8?分辨率。我们也在 4.4 点介绍人的 TRPC3 的结构吗?分辨率。这些结构显示出塑造钟的 cytosolic 层在保持 transmembrane 层的二层的体系结构。包括 N 终端 ankyrin 重复和 C 终端卷卷, cytosolic 领域的广泛的内部子单元的相互作用贡献 tetramer 集会。高亲密关系的禁止者 BTDM 在 S5-S6 毛孔领域和电压之间挤像传感器的领域禁止隧道开。我们的结构揭开 TRPC 隧道的分子的建筑学并且为理解这些隧道的机制提供一个结构的基础。	Qinglin Tang Wenjun Guo Li Zheng Jing-Xiang Wu Meng Liu Xindi Zhou Xiaolin Zhang Lei Chen	2018	Cell Research2018，28，7：	10
	3	Targeting autophagy overcomes cancer-intrinsic resistance to CAR-T immunotherapy in B-cell malignancies显示文摘Background:Chimeric antigen receptor T(CAR-T)therapy has substantially revolutionized the clinical outcomes of patients with hematologic malignan-cies,but the cancer-intrinsic mechanisms underlying resistance to CAR-T cells remain yet to be fully understood.This study aims to explore the molecular deter-minants of cancer cell sensitivity to CAR-T cell-mediated killing and to provide a better understanding of the underlying mechanisms and potential modulation to improve clinical efficacy.Methods:The human whole-genome CRISPR/Cas9-based knockout screening was conducted to identify key genes that enable cancer cells to evade CD19 CAR-T-cell-mediated killing.The in vitro cytotoxicity assays and evaluation of tumor tissue and bone marrow specimens were further conducted to confirm the role of the key genes in cancer cell susceptibility to CAR-T cells.In addition,the specific mechanisms influencing CAR-T cell-mediated cancer clearance were elucidated in mouse and cellular models.Results:The CRISPR/Cas9-based knockout screening showed that the enrich-ment of autophagy-related genes(ATG3,BECN1,and RB1CC1)provided protec-tion of cancer cells from CD19 CAR-T cell-mediated cytotoxicity.These findings were further validated by in vitro cytotoxicity assays in cells with genetic and pharmacological inhibition of autophagy.Notably,higher expression of the three autophagy-related proteins in tumor samples was correlated with poorer respon-siveness and worse survival in patients with relapsed/refractory B-cell lymphoma after CD19 CAR-T therapy.Bulk RNA sequencing analysis of bone marrow samples from B-cell leukemia patients also suggested the clinical relevance of autophagy to the therapeutic response and relapse after CD19 CAR-T cell ther-apy.Pharmacological inhibition of autophagy and knockout of RB1CC1 could dramatically sensitize tumor cells to CD19 CAR-T cell-mediated killing in mouse models of both B-cell leukemia and lymphoma.Moreover,our study revealed that cancer-intrinsic autophagy mediates evasion of CAR-T cells via the TNF-α-TNFR1 axis-mediated apoptosis and STAT1/IRF1-induced chemokine signaling activation.Conclusions:These findings confirm that autophagy signaling in B-cell malig-nancies is essential for the effective cytotoxic function of CAR-T cells and thereby pave the way for the development of autophagy-targeting strategies to improve the clinical efficacy of CAR-T cell immunotherapy.	Lu Tang Huan Zhang Fen Zhou Qiuzhe Wei Mengyi Du Jianghua Wu Chenggong Li Wenjing Luo Jie Zhou Xindi Wang Zhaozhao Chen Yinqiang Zhang Zhongpei Huang Zhuolin Wu Yuxi Wen Huiwen Jiang Danying Liao Haiming Kou Wei Xiong Heng Mei Yu Hu	2024	Cancer Communications2024，44，3：	0

返回顶部每页显示：

共1页首页上一页第1页下一页末页 /1 跳转

goolge学术搜索-维普

网站首页 | 关于我们 | 联系我们 | 产品服务 | 客服中心 | 广告服务 | 版权声明 | 网站联盟 | 友情链接 | 售卡网点

版权所有© 渝B2-20050021-1　渝公网安备 50019002500403号　违法和不良信息举报中心

互联网出版许可证新出网证(渝)字10号全国400电话 - 免长途话费